Pyridoxine improves endothelial function in cardiac transplant recipients

Area of Science:

• Cardiology
• Transplantation Medicine
• Vascular Biology

Background:

• Endothelial dysfunction is prevalent in cardiac transplant recipients and a predictor of transplant coronary artery disease.
• Hyperhomocysteinemia, common in transplant recipients, is linked to endothelial dysfunction and transplant coronary artery disease.
• Therapies reducing homocysteine may improve endothelial function and mitigate transplant coronary artery disease risk.

Purpose of the Study:

• To investigate the impact of folate or pyridoxine supplementation on endothelial function in cardiac transplant recipients.

Main Methods:

• A double-blind, randomized, placebo-controlled trial involving 31 cardiac transplant recipients.
• Participants were assigned to receive pyridoxine (100 mg/day), folate (5 mg/day), or placebo for 10 weeks.
• Endothelial function was assessed using brachial artery flow-mediated dilatation; homocysteine levels were also measured.

Main Results:

• Pyridoxine supplementation led to a significant improvement in endothelial function.
• No significant changes in homocysteine concentrations were observed in any group.
• Folate supplementation or placebo did not result in significant changes in endothelial function.

Conclusions:

• Pyridoxine supplementation, but not folate, significantly enhances endothelial function in cardiac transplant recipients.
• These findings suggest a potential therapeutic role for pyridoxine in managing endothelial dysfunction post-cardiac transplantation.